A Pilot, Randomised, Blinded, Feasibility, Safety and Biochemical and Physiological Efficacy Study of Terlipressin vs. Placebo in Cardiac Surgery Patients with the Post-operative High Cardiac Output and Hypotension syndrome
Austin Health
40 participants
Jun 1, 2018
Interventional
Conditions
Summary
The management of patients who have a high cardiac output (the amount of blood pumped by the heart every minute) and a low blood pressure after open heart surgery is complex because the best way to deliver best post-operative treatment of the circulation is uncertain. However, treatment typically includes the use of fluids given though a vein and drugs to help increase blood pressure to safer levels. Such blood pressure drugs can be useful but can have adverse effects on heart function or cause disturbances of the heart rhythm. Thus, they are often avoided and used very late in the management of these patients when blood pressure is really low. As a consequence, blood pressure may remain undesirably low for a long time and patients may be given large amounts of fluids instead, which can also be undesirable. More recently, however, a medication called terlipressin has been developed to help liver patients who have a high cardiac output with low blood pressure and worsening kidney function. Terlipressin can be given as a single shot through any hand or arm vein and can increase blood pressure for up to 6 hours. Terlipressin offers the opportunity to improve blood pressure management in patients with a high cardiac output and a low blood pressure after heart surgery without the risk of causing heart injury and rhythm disturbances. However, because terlipressin has only been used to support blood pressure in this way in liver patients, we do not know how effective it would be in such selected cardiac surgery patients. In this study we wish to test whether, in open heart surgery patients with a high cardiac output but a low blood pressure, terlipressin is more effective than placebo (dummy injection) at restoring blood pressure and whether such treatment is safe and changes the amount of fluid given and kidney function for the better.
Eligibility
Inclusion Criteria4
- Patients aged 18 years or older
- Admitted to the intensive care unit after cardiopulmonary bypass
- High cardiac index (greater than 3 litres/minute/m2)
- Hypotension (systolic blood pressure less than 90 mmHg or mean arterial blood pressure less than 65 mmHg)
Exclusion Criteria9
- Pregnancty
- Death is considered imminent (within 24 hours)
- Known sever peripheral vascular disease
- Raynaud's phenomenon
- Known allergy to terlipressin
- Unstable angina
- Recent myocardial infarction
- Asthma
- Surgery for coronary artery disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous push of Terlipressin (Lucassin) 0.85mg, at baseline as a minimum and then 6 hourly for a maximum of 24 hours with the need for further doses determined by continuous invasive monitoring via an arterial line.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613001194752